Derma Sciences

Derma Sciences is a Medical Devices company specializing in the field of Advanced Wound Care. Currently their major products are Medihoney, Algicell AG, Xtrasorb wound dressing, Bioguard and Mobility1. Their newest product DSC127 - an Angiotensin Analog - is currently in Phase II Pre-Clinical trials.
Type
Public
HQ
Princeton, US
Size (employees)
260 (est)-13%
Derma Sciences is headquartered in Princeton, US

Key People at Derma Sciences

Edward J. Quilty

Edward J. Quilty

Chairman & CEO
Srini Conjeevaram

Srini Conjeevaram

Director
John E. Yetter

John E. Yetter

CFO & Vice President of Finance

Derma Sciences Office Locations

Derma Sciences has offices in Princeton, New York
Princeton, US
New York, US

Derma Sciences Metrics

Derma Sciences Summary

Market capitalization

$198 M

Closing share price

$7
Derma Sciences's current market capitalization is $198 M.

Derma Sciences Financials

Derma Sciences's revenue is $84.5 M in FY, 2015 which is a 0.87% increase from the previous period.
FY, 2015FY, 2014

Revenue

$84.5 M$83.7 M

Revenue growth, %

0.9%

Gross profit

$32.7 M$30.1 M

Operating income

$-22 M$-40.1 M

Operating expense total

$54.7 M$70.2 M

Net Income

$-38.1 M$-39.8 M

Operating cash flow

$-3.58 M$12.9 M

Derma Sciences Market Value History

Derma Sciences Online Presence

Derma Sciences News

Derma Sciences Company Life

You may also be interested in